Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Growth 2026-2032
The global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is a modified form of G-CSF designed to stimulate sustained production and release of neutrophils, a type of white blood cell vital for infection defense, over an extended period. Unlike short-acting G-CSF, which requires daily injections, long-acting G-CSF, such as pegfilgrastim, incorporates a polyethylene glycol (PEG) molecule that slows its breakdown and clearance from the body, allowing for prolonged therapeutic effects and reduced dosing frequency, typically once per chemotherapy cycle.
United States market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) players cover Amgen, Mylan, Kashiv BioSciences, Pfizer, Fresenius Kabi, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Forecast” looks at past sales and reviews total world Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales in 2025, providing a comprehensive analysis by region and market sector of projected Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales for 2026 through 2032. With Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) industry.
This Insight Report provides a comprehensive analysis of the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF).
This report presents a comprehensive overview, market shares, and growth opportunities of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market?
What factors are driving Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market opportunities vary by end market size?
How does Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) break out by Type, by Application?
The report requires updating with new data and is sent in 48 hours after order is placed.
Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is a modified form of G-CSF designed to stimulate sustained production and release of neutrophils, a type of white blood cell vital for infection defense, over an extended period. Unlike short-acting G-CSF, which requires daily injections, long-acting G-CSF, such as pegfilgrastim, incorporates a polyethylene glycol (PEG) molecule that slows its breakdown and clearance from the body, allowing for prolonged therapeutic effects and reduced dosing frequency, typically once per chemotherapy cycle.
United States market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) players cover Amgen, Mylan, Kashiv BioSciences, Pfizer, Fresenius Kabi, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Forecast” looks at past sales and reviews total world Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales in 2025, providing a comprehensive analysis by region and market sector of projected Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales for 2026 through 2032. With Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) industry.
This Insight Report provides a comprehensive analysis of the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF).
This report presents a comprehensive overview, market shares, and growth opportunities of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Pegfilgrastim
- Lenograstim
- Other
- Hospital and Clinic
- Pharmacy
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Amgen
- Mylan
- Kashiv BioSciences
- Pfizer
- Fresenius Kabi
- Coherus BioSciences
- Sandoz
- Italfarmaco SpA
- Evive Biotech
- Chugai Pharmaceutical
- Jiangsu Hengrui Pharmaceuticals
- Amoytop Biotech
- Qilu Pharmaceutical
- CSPC Baike Biopharma
- SL Pharm
- Lunan Pharmaceutical
What is the 10-year outlook for the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market?
What factors are driving Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market opportunities vary by end market size?
How does Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) break out by Type, by Application?
The report requires updating with new data and is sent in 48 hours after order is placed.
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Country/Region, 2021, 2025 & 2032
2.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Type
2.2.1 Pegfilgrastim
2.2.2 Lenograstim
2.2.3 Other
2.2.4 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type
2.2.4.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021-2026)
2.2.4.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sale Price by Type (2021-2026)
2.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Application
2.3.1 Hospital and Clinic
2.3.2 Pharmacy
2.3.3 Other
2.3.4 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application
2.3.4.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sale Market Share by Application (2021-2026)
2.3.4.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Breakdown Data by Company
3.1.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Annual Sales by Company (2021-2026)
3.1.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Company (2021-2026)
3.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Annual Revenue by Company (2021-2026)
3.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Company (2021-2026)
3.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Company (2021-2026)
3.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sale Price by Company
3.4 Key Manufacturers Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Location Distribution
3.4.2 Players Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) BY GEOGRAPHIC REGION
4.1 World Historic Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Geographic Region (2021-2026)
4.1.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country/Region (2021-2026)
4.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Annual Sales by Country/Region (2021-2026)
4.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Annual Revenue by Country/Region (2021-2026)
4.3 Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Growth
4.4 APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Growth
4.5 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Growth
4.6 Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Growth
5 AMERICAS
5.1 Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country
5.1.1 Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026)
5.1.2 Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2026)
5.2 Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026)
5.3 Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region
6.1.1 APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2021-2026)
6.1.2 APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2021-2026)
6.2 APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026)
6.3 APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Country
7.1.1 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026)
7.1.2 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2026)
7.2 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026)
7.3 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Country
8.1.1 Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026)
8.1.2 Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2026)
8.2 Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026)
8.3 Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF)
10.3 Manufacturing Process Analysis of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF)
10.4 Industry Chain Structure of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Distributors
11.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Customer
12 WORLD FORECAST REVIEW FOR LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) BY GEOGRAPHIC REGION
12.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size Forecast by Region
12.1.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Forecast by Region (2027-2032)
12.1.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Forecast by Type (2027-2032)
12.7 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Amgen
13.1.1 Amgen Company Information
13.1.2 Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.1.3 Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Amgen Main Business Overview
13.1.5 Amgen Latest Developments
13.2 Mylan
13.2.1 Mylan Company Information
13.2.2 Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.2.3 Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Mylan Main Business Overview
13.2.5 Mylan Latest Developments
13.3 Kashiv BioSciences
13.3.1 Kashiv BioSciences Company Information
13.3.2 Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.3.3 Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Kashiv BioSciences Main Business Overview
13.3.5 Kashiv BioSciences Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.4.3 Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Fresenius Kabi
13.5.1 Fresenius Kabi Company Information
13.5.2 Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.5.3 Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Fresenius Kabi Main Business Overview
13.5.5 Fresenius Kabi Latest Developments
13.6 Coherus BioSciences
13.6.1 Coherus BioSciences Company Information
13.6.2 Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.6.3 Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Coherus BioSciences Main Business Overview
13.6.5 Coherus BioSciences Latest Developments
13.7 Sandoz
13.7.1 Sandoz Company Information
13.7.2 Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.7.3 Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Sandoz Main Business Overview
13.7.5 Sandoz Latest Developments
13.8 Italfarmaco SpA
13.8.1 Italfarmaco SpA Company Information
13.8.2 Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.8.3 Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Italfarmaco SpA Main Business Overview
13.8.5 Italfarmaco SpA Latest Developments
13.9 Evive Biotech
13.9.1 Evive Biotech Company Information
13.9.2 Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.9.3 Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Evive Biotech Main Business Overview
13.9.5 Evive Biotech Latest Developments
13.10 Chugai Pharmaceutical
13.10.1 Chugai Pharmaceutical Company Information
13.10.2 Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.10.3 Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Chugai Pharmaceutical Main Business Overview
13.10.5 Chugai Pharmaceutical Latest Developments
13.11 Jiangsu Hengrui Pharmaceuticals
13.11.1 Jiangsu Hengrui Pharmaceuticals Company Information
13.11.2 Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.11.3 Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Jiangsu Hengrui Pharmaceuticals Main Business Overview
13.11.5 Jiangsu Hengrui Pharmaceuticals Latest Developments
13.12 Amoytop Biotech
13.12.1 Amoytop Biotech Company Information
13.12.2 Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.12.3 Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Amoytop Biotech Main Business Overview
13.12.5 Amoytop Biotech Latest Developments
13.13 Qilu Pharmaceutical
13.13.1 Qilu Pharmaceutical Company Information
13.13.2 Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.13.3 Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Qilu Pharmaceutical Main Business Overview
13.13.5 Qilu Pharmaceutical Latest Developments
13.14 CSPC Baike Biopharma
13.14.1 CSPC Baike Biopharma Company Information
13.14.2 CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.14.3 CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 CSPC Baike Biopharma Main Business Overview
13.14.5 CSPC Baike Biopharma Latest Developments
13.15 SL Pharm
13.15.1 SL Pharm Company Information
13.15.2 SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.15.3 SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 SL Pharm Main Business Overview
13.15.5 SL Pharm Latest Developments
13.16 Lunan Pharmaceutical
13.16.1 Lunan Pharmaceutical Company Information
13.16.2 Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.16.3 Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Lunan Pharmaceutical Main Business Overview
13.16.5 Lunan Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Country/Region, 2021, 2025 & 2032
2.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Type
2.2.1 Pegfilgrastim
2.2.2 Lenograstim
2.2.3 Other
2.2.4 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type
2.2.4.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021-2026)
2.2.4.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sale Price by Type (2021-2026)
2.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Application
2.3.1 Hospital and Clinic
2.3.2 Pharmacy
2.3.3 Other
2.3.4 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application
2.3.4.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sale Market Share by Application (2021-2026)
2.3.4.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Breakdown Data by Company
3.1.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Annual Sales by Company (2021-2026)
3.1.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Company (2021-2026)
3.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Annual Revenue by Company (2021-2026)
3.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Company (2021-2026)
3.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Company (2021-2026)
3.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sale Price by Company
3.4 Key Manufacturers Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Location Distribution
3.4.2 Players Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) BY GEOGRAPHIC REGION
4.1 World Historic Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Geographic Region (2021-2026)
4.1.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country/Region (2021-2026)
4.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Annual Sales by Country/Region (2021-2026)
4.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Annual Revenue by Country/Region (2021-2026)
4.3 Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Growth
4.4 APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Growth
4.5 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Growth
4.6 Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Growth
5 AMERICAS
5.1 Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country
5.1.1 Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026)
5.1.2 Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2026)
5.2 Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026)
5.3 Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region
6.1.1 APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2021-2026)
6.1.2 APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2021-2026)
6.2 APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026)
6.3 APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Country
7.1.1 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026)
7.1.2 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2026)
7.2 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026)
7.3 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Country
8.1.1 Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026)
8.1.2 Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2026)
8.2 Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026)
8.3 Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF)
10.3 Manufacturing Process Analysis of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF)
10.4 Industry Chain Structure of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Distributors
11.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Customer
12 WORLD FORECAST REVIEW FOR LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) BY GEOGRAPHIC REGION
12.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size Forecast by Region
12.1.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Forecast by Region (2027-2032)
12.1.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Forecast by Type (2027-2032)
12.7 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Amgen
13.1.1 Amgen Company Information
13.1.2 Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.1.3 Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Amgen Main Business Overview
13.1.5 Amgen Latest Developments
13.2 Mylan
13.2.1 Mylan Company Information
13.2.2 Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.2.3 Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Mylan Main Business Overview
13.2.5 Mylan Latest Developments
13.3 Kashiv BioSciences
13.3.1 Kashiv BioSciences Company Information
13.3.2 Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.3.3 Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Kashiv BioSciences Main Business Overview
13.3.5 Kashiv BioSciences Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.4.3 Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Fresenius Kabi
13.5.1 Fresenius Kabi Company Information
13.5.2 Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.5.3 Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Fresenius Kabi Main Business Overview
13.5.5 Fresenius Kabi Latest Developments
13.6 Coherus BioSciences
13.6.1 Coherus BioSciences Company Information
13.6.2 Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.6.3 Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Coherus BioSciences Main Business Overview
13.6.5 Coherus BioSciences Latest Developments
13.7 Sandoz
13.7.1 Sandoz Company Information
13.7.2 Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.7.3 Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Sandoz Main Business Overview
13.7.5 Sandoz Latest Developments
13.8 Italfarmaco SpA
13.8.1 Italfarmaco SpA Company Information
13.8.2 Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.8.3 Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Italfarmaco SpA Main Business Overview
13.8.5 Italfarmaco SpA Latest Developments
13.9 Evive Biotech
13.9.1 Evive Biotech Company Information
13.9.2 Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.9.3 Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Evive Biotech Main Business Overview
13.9.5 Evive Biotech Latest Developments
13.10 Chugai Pharmaceutical
13.10.1 Chugai Pharmaceutical Company Information
13.10.2 Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.10.3 Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Chugai Pharmaceutical Main Business Overview
13.10.5 Chugai Pharmaceutical Latest Developments
13.11 Jiangsu Hengrui Pharmaceuticals
13.11.1 Jiangsu Hengrui Pharmaceuticals Company Information
13.11.2 Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.11.3 Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Jiangsu Hengrui Pharmaceuticals Main Business Overview
13.11.5 Jiangsu Hengrui Pharmaceuticals Latest Developments
13.12 Amoytop Biotech
13.12.1 Amoytop Biotech Company Information
13.12.2 Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.12.3 Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Amoytop Biotech Main Business Overview
13.12.5 Amoytop Biotech Latest Developments
13.13 Qilu Pharmaceutical
13.13.1 Qilu Pharmaceutical Company Information
13.13.2 Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.13.3 Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Qilu Pharmaceutical Main Business Overview
13.13.5 Qilu Pharmaceutical Latest Developments
13.14 CSPC Baike Biopharma
13.14.1 CSPC Baike Biopharma Company Information
13.14.2 CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.14.3 CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 CSPC Baike Biopharma Main Business Overview
13.14.5 CSPC Baike Biopharma Latest Developments
13.15 SL Pharm
13.15.1 SL Pharm Company Information
13.15.2 SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.15.3 SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 SL Pharm Main Business Overview
13.15.5 SL Pharm Latest Developments
13.16 Lunan Pharmaceutical
13.16.1 Lunan Pharmaceutical Company Information
13.16.2 Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
13.16.3 Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Lunan Pharmaceutical Main Business Overview
13.16.5 Lunan Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Pegfilgrastim
Table 4. Major Players of Lenograstim
Table 5. Major Players of Other
Table 6. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026) & (K Units)
Table 7. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021-2026)
Table 8. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021-2026) & ($ million)
Table 9. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2021-2026)
Table 10. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sale by Application (2021-2026) & (K Units)
Table 12. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sale Market Share by Application (2021-2026)
Table 13. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021-2026) & ($ million)
Table 14. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2021-2026)
Table 15. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sale Price by Application (2021-2026) & (US$/Unit)
Table 16. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Company (2021-2026) & (K Units)
Table 17. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Company (2021-2026)
Table 18. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Company (2021-2026) & ($ millions)
Table 19. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Company (2021-2026)
Table 20. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sale Price by Company (2021-2026) & (US$/Unit)
Table 21. Key Manufacturers Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Producing Area Distribution and Sales Area
Table 22. Players Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Products Offered
Table 23. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Geographic Region (2021-2026) & (K Units)
Table 27. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share Geographic Region (2021-2026)
Table 28. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country/Region (2021-2026) & (K Units)
Table 31. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country/Region (2021-2026)
Table 32. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (K Units)
Table 35. Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021-2026)
Table 36. Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026) & (K Units)
Table 38. Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2026) & (K Units)
Table 39. APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2021-2026) & (K Units)
Table 40. APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region (2021-2026)
Table 41. APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026) & (K Units)
Table 43. APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2026) & (K Units)
Table 44. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (K Units)
Table 45. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026) & (K Units)
Table 47. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2026) & (K Units)
Table 48. Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (K Units)
Table 49. Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026) & (K Units)
Table 51. Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2026) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF)
Table 53. Key Market Challenges & Risks of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF)
Table 54. Key Industry Trends of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF)
Table 55. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Distributors List
Table 58. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Customer List
Table 59. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Forecast by Region (2027-2032) & (K Units)
Table 60. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Forecast by Country (2027-2032) & (K Units)
Table 62. Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Forecast by Region (2027-2032) & (K Units)
Table 64. APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Forecast by Type (2027-2032) & (K Units)
Table 70. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Forecast by Application (2027-2032) & (K Units)
Table 72. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. Amgen Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 74. Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 75. Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Amgen Main Business
Table 77. Amgen Latest Developments
Table 78. Mylan Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 79. Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 80. Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Mylan Main Business
Table 82. Mylan Latest Developments
Table 83. Kashiv BioSciences Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 84. Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 85. Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Kashiv BioSciences Main Business
Table 87. Kashiv BioSciences Latest Developments
Table 88. Pfizer Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 89. Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 90. Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Pfizer Main Business
Table 92. Pfizer Latest Developments
Table 93. Fresenius Kabi Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 94. Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 95. Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Fresenius Kabi Main Business
Table 97. Fresenius Kabi Latest Developments
Table 98. Coherus BioSciences Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 99. Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 100. Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Coherus BioSciences Main Business
Table 102. Coherus BioSciences Latest Developments
Table 103. Sandoz Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 104. Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 105. Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Sandoz Main Business
Table 107. Sandoz Latest Developments
Table 108. Italfarmaco SpA Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 109. Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 110. Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Italfarmaco SpA Main Business
Table 112. Italfarmaco SpA Latest Developments
Table 113. Evive Biotech Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 114. Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 115. Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Evive Biotech Main Business
Table 117. Evive Biotech Latest Developments
Table 118. Chugai Pharmaceutical Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 119. Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 120. Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. Chugai Pharmaceutical Main Business
Table 122. Chugai Pharmaceutical Latest Developments
Table 123. Jiangsu Hengrui Pharmaceuticals Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 124. Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 125. Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Jiangsu Hengrui Pharmaceuticals Main Business
Table 127. Jiangsu Hengrui Pharmaceuticals Latest Developments
Table 128. Amoytop Biotech Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 129. Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 130. Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. Amoytop Biotech Main Business
Table 132. Amoytop Biotech Latest Developments
Table 133. Qilu Pharmaceutical Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 134. Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 135. Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 136. Qilu Pharmaceutical Main Business
Table 137. Qilu Pharmaceutical Latest Developments
Table 138. CSPC Baike Biopharma Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 139. CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 140. CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 141. CSPC Baike Biopharma Main Business
Table 142. CSPC Baike Biopharma Latest Developments
Table 143. SL Pharm Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 144. SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 145. SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 146. SL Pharm Main Business
Table 147. SL Pharm Latest Developments
Table 148. Lunan Pharmaceutical Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 149. Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 150. Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 151. Lunan Pharmaceutical Main Business
Table 152. Lunan Pharmaceutical Latest Developments
Table 1. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Pegfilgrastim
Table 4. Major Players of Lenograstim
Table 5. Major Players of Other
Table 6. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026) & (K Units)
Table 7. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021-2026)
Table 8. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021-2026) & ($ million)
Table 9. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2021-2026)
Table 10. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sale by Application (2021-2026) & (K Units)
Table 12. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sale Market Share by Application (2021-2026)
Table 13. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021-2026) & ($ million)
Table 14. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2021-2026)
Table 15. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sale Price by Application (2021-2026) & (US$/Unit)
Table 16. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Company (2021-2026) & (K Units)
Table 17. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Company (2021-2026)
Table 18. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Company (2021-2026) & ($ millions)
Table 19. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Company (2021-2026)
Table 20. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sale Price by Company (2021-2026) & (US$/Unit)
Table 21. Key Manufacturers Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Producing Area Distribution and Sales Area
Table 22. Players Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Products Offered
Table 23. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Geographic Region (2021-2026) & (K Units)
Table 27. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share Geographic Region (2021-2026)
Table 28. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country/Region (2021-2026) & (K Units)
Table 31. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country/Region (2021-2026)
Table 32. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (K Units)
Table 35. Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021-2026)
Table 36. Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026) & (K Units)
Table 38. Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2026) & (K Units)
Table 39. APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2021-2026) & (K Units)
Table 40. APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region (2021-2026)
Table 41. APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026) & (K Units)
Table 43. APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2026) & (K Units)
Table 44. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (K Units)
Table 45. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026) & (K Units)
Table 47. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2026) & (K Units)
Table 48. Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (K Units)
Table 49. Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026) & (K Units)
Table 51. Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2026) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF)
Table 53. Key Market Challenges & Risks of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF)
Table 54. Key Industry Trends of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF)
Table 55. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Distributors List
Table 58. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Customer List
Table 59. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Forecast by Region (2027-2032) & (K Units)
Table 60. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Forecast by Country (2027-2032) & (K Units)
Table 62. Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Forecast by Region (2027-2032) & (K Units)
Table 64. APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Forecast by Type (2027-2032) & (K Units)
Table 70. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Forecast by Application (2027-2032) & (K Units)
Table 72. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. Amgen Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 74. Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 75. Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Amgen Main Business
Table 77. Amgen Latest Developments
Table 78. Mylan Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 79. Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 80. Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Mylan Main Business
Table 82. Mylan Latest Developments
Table 83. Kashiv BioSciences Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 84. Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 85. Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Kashiv BioSciences Main Business
Table 87. Kashiv BioSciences Latest Developments
Table 88. Pfizer Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 89. Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 90. Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Pfizer Main Business
Table 92. Pfizer Latest Developments
Table 93. Fresenius Kabi Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 94. Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 95. Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Fresenius Kabi Main Business
Table 97. Fresenius Kabi Latest Developments
Table 98. Coherus BioSciences Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 99. Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 100. Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Coherus BioSciences Main Business
Table 102. Coherus BioSciences Latest Developments
Table 103. Sandoz Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 104. Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 105. Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Sandoz Main Business
Table 107. Sandoz Latest Developments
Table 108. Italfarmaco SpA Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 109. Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 110. Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Italfarmaco SpA Main Business
Table 112. Italfarmaco SpA Latest Developments
Table 113. Evive Biotech Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 114. Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 115. Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Evive Biotech Main Business
Table 117. Evive Biotech Latest Developments
Table 118. Chugai Pharmaceutical Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 119. Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 120. Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. Chugai Pharmaceutical Main Business
Table 122. Chugai Pharmaceutical Latest Developments
Table 123. Jiangsu Hengrui Pharmaceuticals Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 124. Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 125. Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Jiangsu Hengrui Pharmaceuticals Main Business
Table 127. Jiangsu Hengrui Pharmaceuticals Latest Developments
Table 128. Amoytop Biotech Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 129. Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 130. Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. Amoytop Biotech Main Business
Table 132. Amoytop Biotech Latest Developments
Table 133. Qilu Pharmaceutical Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 134. Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 135. Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 136. Qilu Pharmaceutical Main Business
Table 137. Qilu Pharmaceutical Latest Developments
Table 138. CSPC Baike Biopharma Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 139. CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 140. CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 141. CSPC Baike Biopharma Main Business
Table 142. CSPC Baike Biopharma Latest Developments
Table 143. SL Pharm Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 144. SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 145. SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 146. SL Pharm Main Business
Table 147. SL Pharm Latest Developments
Table 148. Lunan Pharmaceutical Basic Information, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturing Base, Sales Area and Its Competitors
Table 149. Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolios and Specifications
Table 150. Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 151. Lunan Pharmaceutical Main Business
Table 152. Lunan Pharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Picture of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF)
Figure 2. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country/Region (2025)
Figure 10. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Pegfilgrastim
Figure 12. Product Picture of Lenograstim
Figure 13. Product Picture of Other
Figure 14. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type in 2026
Figure 15. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2021-2026)
Figure 16. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Consumed in Hospital and Clinic
Figure 17. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market: Hospital and Clinic (2021-2026) & (K Units)
Figure 18. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Consumed in Pharmacy
Figure 19. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market: Pharmacy (2021-2026) & (K Units)
Figure 20. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Consumed in Other
Figure 21. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market: Other (2021-2026) & (K Units)
Figure 22. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sale Market Share by Application (2025)
Figure 23. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application in 2026
Figure 24. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Company in 2026 (K Units)
Figure 25. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Company in 2026
Figure 26. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Company in 2026 ($ millions)
Figure 27. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Company in 2026
Figure 28. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Geographic Region (2021-2026)
Figure 29. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Geographic Region in 2026
Figure 30. Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales 2021-2026 (K Units)
Figure 31. Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue 2021-2026 ($ millions)
Figure 32. APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales 2021-2026 (K Units)
Figure 33. APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue 2021-2026 ($ millions)
Figure 34. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales 2021-2026 (K Units)
Figure 35. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue 2021-2026 ($ millions)
Figure 36. Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales 2021-2026 (K Units)
Figure 37. Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue 2021-2026 ($ millions)
Figure 38. Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country in 2026
Figure 39. Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2021-2026)
Figure 40. Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021-2026)
Figure 41. Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2021-2026)
Figure 42. United States Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 43. Canada Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 44. Mexico Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 45. Brazil Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 46. APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region in 2026
Figure 47. APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region (2021-2026)
Figure 48. APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021-2026)
Figure 49. APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2021-2026)
Figure 50. China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 51. Japan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 52. South Korea Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 53. Southeast Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 54. India Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 55. Australia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 56. China Taiwan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 57. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country in 2026
Figure 58. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2021-2026)
Figure 59. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021-2026)
Figure 60. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2021-2026)
Figure 61. Germany Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 62. France Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 63. UK Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 64. Italy Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 65. Russia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 66. Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021-2026)
Figure 67. Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021-2026)
Figure 68. Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2021-2026)
Figure 69. Egypt Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 70. South Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 71. Israel Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 72. Turkey Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 73. GCC Countries Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) in 2026
Figure 75. Manufacturing Process Analysis of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF)
Figure 76. Industry Chain Structure of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF)
Figure 77. Channels of Distribution
Figure 78. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Forecast by Region (2027-2032)
Figure 79. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share Forecast by Region (2027-2032)
Figure 80. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share Forecast by Type (2027-2032)
Figure 81. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share Forecast by Type (2027-2032)
Figure 82. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share Forecast by Application (2027-2032)
Figure 83. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF)
Figure 2. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country/Region (2025)
Figure 10. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Pegfilgrastim
Figure 12. Product Picture of Lenograstim
Figure 13. Product Picture of Other
Figure 14. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type in 2026
Figure 15. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2021-2026)
Figure 16. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Consumed in Hospital and Clinic
Figure 17. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market: Hospital and Clinic (2021-2026) & (K Units)
Figure 18. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Consumed in Pharmacy
Figure 19. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market: Pharmacy (2021-2026) & (K Units)
Figure 20. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Consumed in Other
Figure 21. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market: Other (2021-2026) & (K Units)
Figure 22. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sale Market Share by Application (2025)
Figure 23. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application in 2026
Figure 24. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Company in 2026 (K Units)
Figure 25. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Company in 2026
Figure 26. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Company in 2026 ($ millions)
Figure 27. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Company in 2026
Figure 28. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Geographic Region (2021-2026)
Figure 29. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Geographic Region in 2026
Figure 30. Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales 2021-2026 (K Units)
Figure 31. Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue 2021-2026 ($ millions)
Figure 32. APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales 2021-2026 (K Units)
Figure 33. APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue 2021-2026 ($ millions)
Figure 34. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales 2021-2026 (K Units)
Figure 35. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue 2021-2026 ($ millions)
Figure 36. Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales 2021-2026 (K Units)
Figure 37. Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue 2021-2026 ($ millions)
Figure 38. Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country in 2026
Figure 39. Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2021-2026)
Figure 40. Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021-2026)
Figure 41. Americas Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2021-2026)
Figure 42. United States Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 43. Canada Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 44. Mexico Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 45. Brazil Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 46. APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region in 2026
Figure 47. APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region (2021-2026)
Figure 48. APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021-2026)
Figure 49. APAC Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2021-2026)
Figure 50. China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 51. Japan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 52. South Korea Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 53. Southeast Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 54. India Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 55. Australia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 56. China Taiwan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 57. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country in 2026
Figure 58. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2021-2026)
Figure 59. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021-2026)
Figure 60. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2021-2026)
Figure 61. Germany Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 62. France Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 63. UK Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 64. Italy Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 65. Russia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 66. Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021-2026)
Figure 67. Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021-2026)
Figure 68. Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2021-2026)
Figure 69. Egypt Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 70. South Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 71. Israel Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 72. Turkey Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 73. GCC Countries Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth 2021-2026 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) in 2026
Figure 75. Manufacturing Process Analysis of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF)
Figure 76. Industry Chain Structure of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF)
Figure 77. Channels of Distribution
Figure 78. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Forecast by Region (2027-2032)
Figure 79. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share Forecast by Region (2027-2032)
Figure 80. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share Forecast by Type (2027-2032)
Figure 81. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share Forecast by Type (2027-2032)
Figure 82. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share Forecast by Application (2027-2032)
Figure 83. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share Forecast by Application (2027-2032)
